Want to see ROIV full AI Analyst Report?
ROIV Stock Chart & Stats
$35.01
-$0.09(-0.26%)
At close: 4:00 PM EDT
$35.01
-$0.09(-0.26%)
Day’s Range― - ―
52-Week Range$10.90 - $37.00
Previous CloseN/A
Volume4.04M
Average Volume (3M)5.59M
Market Cap
$24.94B
Enterprise Value$19.08K
Total Cash (Recent Filing)$4.30B
Total Debt (Recent Filing)$107.44M
Price to Earnings (P/E)―
Beta0.76
Next Earnings
Aug 06, 2026EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.45
Shares Outstanding722,406,250
10 Day Avg. Volume4,163,867
30 Day Avg. Volume5,587,777
Financial Highlights & Ratios
PEG Ratio-0.81
Price to Book (P/B)4.25
Price to Sales (P/S)2326.88
P/FCF Ratio-25.34
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$36.61Price Target Upside4.58% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.24
Revenue Forecast (FY)$61.60M
Bulls Say, Bears Say
Bulls Say
Well-capitalized Balance Sheet With Very Low LeverageRoivant's large equity base and negligible debt provide durable financial flexibility for long drug development cycles. This capital strength supports continued R&D, trial enrollment and commercial preparations without immediate refinancing pressure, preserving optionality through pivotal readouts.
High Gross ProfitabilityA ~91% gross margin indicates scalable economics for approved therapies and favorable product-level profitability once commercialization scales. High gross margins can sustain operating leverage as revenues grow, improving ability to absorb fixed R&D and SG&A as programs transition to market.
Pipeline Execution And Regulatory ProgressDemonstrated rapid enrollment, meaningful early efficacy signals and regulatory recognition (Breakthrough Therapy) materially increase the probability of near-term value realization. Sustained execution across multiple programs diversifies binary risk and strengthens long-term commercial optionality if approvals follow.
Bears Say
Substantial And Persistent Cash BurnLarge negative operating and free cash flows indicate the company is consuming capital to fund development. Even with strong cash reserves, persistent burn raises the need for future monetizations, partnerships, or dilutive financing and constrains runway if programs face delays or failures.
Large Operating Losses And Shrinking RevenueSustained multi-hundred-million dollar losses and a steep revenue decline imply the business is not yet generating returns on invested capital. This structural profitability gap increases reliance on successful clinical outcomes and commercialization to reverse trends and justify ongoing investment.
Clinical Interpretability And Endpoint Risk For IMVT-1402Open-label Period 1 data may overestimate effect sizes versus controlled trials, while a short randomized-withdrawal primary endpoint risks failing to show separation despite clinical benefit. This structural trial-design risk could delay approval or require additional studies, impacting long-term prospects.
Roivant Sciences News
ROIV FAQ
What was Roivant Sciences Ltd.’s price range in the past 12 months?
Roivant Sciences Ltd. lowest stock price was $10.90 and its highest was $37.00 in the past 12 months.
What is Roivant Sciences Ltd.’s market cap?
Roivant Sciences Ltd.’s market cap is $24.94B.
When is Roivant Sciences Ltd.’s upcoming earnings report date?
Roivant Sciences Ltd.’s upcoming earnings report date is Aug 06, 2026 which is in 5 days.
How were Roivant Sciences Ltd.’s earnings last quarter?
Roivant Sciences Ltd. released its earnings results on May 20, 2026. The company reported $0.279 earnings per share for the quarter, beating the consensus estimate of -$0.289 by $0.568.
Is Roivant Sciences Ltd. overvalued?
According to Wall Street analysts Roivant Sciences Ltd.’s price is currently Undervalued.
Does Roivant Sciences Ltd. pay dividends?
Roivant Sciences Ltd. does not currently pay dividends.
What is Roivant Sciences Ltd.’s EPS estimate?
Roivant Sciences Ltd.’s EPS estimate is -0.29.
How many shares outstanding does Roivant Sciences Ltd. have?
Roivant Sciences Ltd. has 722,406,250 shares outstanding.
What happened to Roivant Sciences Ltd.’s price movement after its last earnings report?
Roivant Sciences Ltd. reported an EPS of $0.279 in its last earnings report, beating expectations of -$0.289. Following the earnings report the stock price went up 14.888%.
Which hedge fund is a major shareholder of Roivant Sciences Ltd.?
Currently, no hedge funds are holding shares in ROIV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Roivant Sciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$36.61 (4.58% Upside)
$36.61 (4.58% Upside)
Blogger Sentiment
Neutral
ROIV Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 10.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $209.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 2.4%
Last 30 Days ▲ 2.5%
Last 30 Days ▲ 2.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
207.64%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
5.35%
Trailing 12-Months
Company Description
Roivant Sciences Ltd.
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.
ROIV Company Deck
ROIV Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted multiple strong clinical signals (notably the robust open-label 1402 RA responses and mosli hemodynamic activity), solid financial backing (cash of $4.3B and a $2.25B Moderna settlement), and rapid execution across trials and commercial prep. Key risks were acknowledged: interpretability limitations from open-label data, potential difficulty meeting the randomized withdrawal primary endpoint for 1402, some program failures (bitokamab), pending biomarker analyses, and competitive/ regulatory hurdles in indications like CLE and PH-ILD. On balance, the pipeline momentum, cash position, and high-impact data presented outweigh the noted challenges, though important uncertainties remain that will require follow-up data and regulatory feedback.View all ROIV earnings summariesROIV Stock 12 Month Forecast
Average Price Target
$36.61
▲(4.58% Upside)
Technical Analysis
Ownership Overview
19.51% Insiders
16.92% Mutual Funds
1.81% Other Institutional Investors
47.32% Public Companies and
Individual Investors